Improved immunotoxins with novel functional elements

Current Pharmaceutical Design

Volumn 15, Issue 23, 2009, Pages 2700-2711

  Hetzel, C ^a   Bachran, C ^b   Tur, Mehmet Kemal ^c   Fuchs, H ^b   Stöcker, Michael ^c  

^a FRAUNHOFER INSTITUTE FOR MOLECULAR BIOLOGY AND APPLIED ECOLOGY IME   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; CASPASE 7; CELL PENETRATING PEPTIDE; CETUXIMAB; CHEMOKINE RECEPTOR CXCR4; DIPHTHERIA TOXIN; IMMUNOTOXIN; INTERLEUKIN 1BETA CONVERTING ENZYME; PROTEIN P53; RETINOIC ACID; SAPORIN; TRANSACTIVATOR PROTEIN;

ANTIGEN BINDING; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BINDING AFFINITY; BINDING SITE; CANCER CELL; CYTOTOXICITY TEST; DRUG HALF LIFE; DRUG POTENCY; DRUG TARGETING; DRUG UPTAKE; GENE EXPRESSION; HUMAN; IMMUNOGENICITY; NONHUMAN; PRIORITY JOURNAL; REVIEW; TARGET CELL DESTRUCTION;

ANTINEOPLASTIC AGENTS; BINDING SITES, ANTIBODY; CELL DEATH; DRUG DELIVERY SYSTEMS; HUMANS; IMMUNOTOXINS; MODELS, BIOLOGICAL; MODELS, IMMUNOLOGICAL; RECOMBINANT PROTEINS;

EID: 70350150330     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161209788923930     Document Type: Review

References (181)

1. Ehrlich P. The collected papers of Paul Ehrlich. In: Himmelweite F, Marquardt M, Doles H, Eds. Oxford: Pergamon Press 1956; pp. 596-618.
2. Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975; 256(5517): 495-7.
3. Pastan I, Hassan R, FitzGerald DJ, Kreitman RJ. Immunotoxin treatment of cancer. Annual review of medicine 2007; 58: 221-37.
4. Kreitman RJ. Immunotoxins. Expert Opin Pharmacother 2000; 1(6): 1117-29.
5. Frankel AE, Kreitman RJ, Sausville EA. Targeted toxins. Clin Cancer Res 2000; 6(2): 326-34.
6. Kreitman RJ. Toxin-labeled monoclonal antibodies. Curr Pharmaceut Biotechnol 2001; 2(4): 313-25.
7. Colcher D, Pavlinkova G, Beresford G, Booth BJ, Choudhury A, Batra SK. Pharmacokinetics and biodistribution of genetically-engineered antibodies. Q J Nucl Med 1998; 42(4): 225-41.
8. Pastan I, Hassan R, Fitzgerald DJ, Kreitman RJ. Immunotoxin therapy of cancer. Nat Rev Cancer 2006; 6(7): 559-65.
9. Kuan CT, Pai LH, Pastan I. Immunotoxins containing Pseudomonas exotoxin that target LeY damage human endothelial cells in an antibody-specific mode: Relevance to vascular leak syndrome. Clin Cancer Res 1995; 1(12): 1589-94.
10. Lindstrom AL, Erlandsen SL, Kersey JH, Pennell CA. An in vitro model for toxin-mediated vascular leak syndrome: Ricin toxin A chain increases the permeability of human endothelial cell monolayers. Blood 1997; 90(6): 2323-34.
11. Vallera DA, Carroll SF, Snover DC, Carlson GJ, Blazar BR. Toxicity and efficacy of anti-T-cell ricin toxin A chain immunotoxins in a murine model of established graft-versus-host disease induced across the major histocompatibility barrier. Blood 1991; 77(1): 182-94.
12. Chaudry GJ, Fulton RJ, Draper RK. A variant of exotoxin A that forms potent and specific chemically conjugated immunotoxins. J Biolog Chem 1993; 268(13): 9437-41.
13. Baluna R, Rizo J, Gordon BE, Ghetie V, Vitetta ES. Evidence for a structural motif in toxins and interleukin-2 that may be responsible for binding to endothelial cells and initiating vascular leak syndrome. Proceed Natl Acad Sci USA 1999; 96(7): 3957-62.
14. Engert A, Diehl V, Schnell R, Radszuhn A, Hatwig MT, Drillich S, et al. A phase-I study of an anti-CD25 ricin A-chain immunotoxin (RFT5-SMPT-dgA) in patients with refractory Hodgkin's lymphoma. Blood 1997; 89(2): 403-10.
15. Kreitman RJ. Immunotoxins in cancer therapy. Curr Opin Immunol 1999; 11(5): 570-8.
16. Posey JA, Khazaeli MB, Bookman MA, Nowrouzi A, Grizzle WE, Thornton J, et al. A phase I trial of the single-chain immunotoxin SGN-10 (BR96 sFv-PE40) in patients with advanced solid tumors. Clin Cancer Res 2002; 8(10): 3092-9.
17. Saleh MN, Sugarman S, Murray J, Ostroff JB, Healey D, Jones D, et al. Phase I trial of the anti-Lewis Y drug immunoconjugate BR96-doxorubicin in patients with lewis Y-expressing epithelial tumors. J Clin Oncol 2000; 18(11): 2282-92.
18. Sausville EA, Headlee D, Stetler-Stevenson M, Jaffe ES, Solomon D, Figg WD, et al. Continuous infusion of the anti-CD22 immunotoxin IgG-RFB4-SMPT-dgA in patients with B-cell lymphoma: A phase I study. Blood 1995; 85(12): 3457-65.
19. Khandare JJ, Minko T. Antibodies and peptides in cancer therapy. Crit Rev Therapeut Drug Carrier Sys 2006; 23(5): 401-35.
20. Lorimer IA, Wikstrand CJ, Batra SK, Bigner DD, Pastan I. Immunotoxins that target an oncogenic mutant epidermal growth factor receptor expressed in human tumors. Clin Cancer Res 1995; 1(8): 859-64.
21. Lorimer IA, Keppler-Hafkemeyer A, Beers RA, Pegram CN, Bigner DD, Pastan I. Recombinant immunotoxins specific for a mutant epidermal growth factor receptor: Targeting with a single chain antibody variable domain isolated by phage display. Proc Natl Acad Sci USA 1996; 93(25): 14815-20.
22. Marsh JW, Klinman DM. Development of a diphtheria toxin mutant conjugate directed against antigen-specific B cells expressing high affinity surface Ig. J Immunol 1990; 144(3): 1046-51.
23. Nachreiner T, Kampmeier F, Thepen T, Fischer R, Barth S, Stöcker M. Depletion of autoreactive B-lymphocytes by a recombinant myelin oligodendrocyte glycoprotein-based immunotoxin. J Neuroimmunol 2008; 195(1-2): 28-35.
24. Stöcker M, Klockenbring T, Huhn M, Nachreiner T, Wicklein D, Petersen A, et al. Antigen-specific targeting and elimination of EBV-transformed B cells by allergen toxins. J Allergy Clin Immunol 2005; 116(4): 910-5.
25. Fuchs H, Bachran C, Li T, Heisler I, Durkop H, Sutherland M. A cleavable molecular adapter reduces side effects and concomitantly enhances efficacy in tumor treatment by targeted toxins in mice. J Control Release 2007; 117(3): 342-50.
26. Heisler I, Keller J, Tauber R, Sutherland M, Fuchs H. A cleavable adapter to reduce nonspecific cytotoxicity of recombinant immunotoxins. Int J Cancer 2003; 103(2): 277-82.
27. Azemar M, Djahansouzi S, Jager E, Solbach C, Schmidt M, Maurer AB, et al. Regression of cutaneous tumor lesions in patients intra-tumorally injected with a recombinant single-chain antibody-toxin targeted to ErbB2/HER2. Breast Cancer Res Treat 2003; 82(3): 155-64.
28. Kitamura K, Takahashi T, Kotani T, Miyagaki T, Yamaoka N, Tsurumi H, et al. Local administration of monoclonal antibody-drug conjugate: A new strategy to reduce the local recurrence of colorectal cancer. Cancer Res 1992; 52(22): 6323-8.
29. Nagata S, Ise T, Onda M, Nakamura K, Ho M, Raubitschek A, et al. Cell membrane-specific epitopes on CD30: Potentially superior targets for immunotherapy. Proc Natl Acad Sci USA 2005; 102(22): 7946-51.
30. Horn-Lohrens O, Tiemann M, Lange H, Kobarg J, Hafner M, Hansen H, et al. Shedding of the soluble form of CD30 from the Hodgkin-analogous cell line L540 is strongly inhibited by a new CD30-specific antibody (Ki-4). Int J Cancer 1995; 60(4): 539-44.
31. Aina OH, Liu R, Sutcliffe JL, Marik J, Pan CX, Lam KS. From combinatorial chemistry to cancer-targeting peptides. Mol Pharm 2007; 4(5): 631-51.
32. Almagro JC, Fransson J. Humanization of antibodies. Front Biosci 2008; 13: 1619-33.
33. Benhar I. Design of synthetic antibody libraries. Expert Opin Biolog Ther 2007; 7(5): 763-79.
34. Lonberg N. Human monoclonal antibodies from transgenic mice. Handb Exper Pharmacol 2008; (181): 69-97.
35. Mondon P, Dubreuil O, Bouayadi K, Kharrat H. Human antibody libraries: A race to engineer and explore a larger diversity. Front Biosci 2008; 13: 1117-29.
36. Hoogenboom HR, de Bruine AP, Hufton SE, Hoet RM, Arends JW, Roovers RC. Antibody phage display technology and its applications. Immunotechnology 1998; 4(1): 1-20.
37. Zahnd C, Amstutz P, Pluckthun A. Ribosome display: Selecting and evolving proteins in vitro that specifically bind to a target. Nat Methods 2007; 4(3): 269-79.
38. Nielsen UB, Marks JD. Internalizing antibodies and targeted cancer therapy: Direct selection from phage display libraries. Pharmaceut Sci Technol Today 2000; 3(8): 282-91.
39. Sandvig K, van Deurs B. Endocytosis and intracellular sorting of ricin and Shiga toxin. FEBS Lett 1994; 346(1): 99-102.
40. Kuan CT, Wikstrand CJ, Archer G, Beers R, Pastan I, Zalutsky MR, et al. Increased binding affinity enhances targeting of glioma xenografts by EGFRvIII-specific scFv. Int J Cancer 2000; 88(6): 962-9.
41. Maier LA, Xu FJ, Hester S, Boyer CM, McKenzie S, Bruskin AM, et al. Requirements for the internalization of a murine monoclonal antibody directed against the HER-2/neu gene product c-erbB-2. Cancer Res 1991; 51(19): 5361-9.
42. Pirker R. Immunotoxins against solid tumors. J Cancer Res Clin Oncol 1988; 114(4): 385-93.
43. Shih LB, Goldenberg DM, Xuan H, Lu HW, Mattes MJ, Hall TC. Internalization of an intact doxorubicin immunoconjugate. Cancer Immunol Immunother 1994; 38(2): 92-8.
44. van Oosterhout YV, van den Herik-Oudijk IE, Wessels HM, de Witte T, van de Winkel JG, Preijers FW. Effect of isotype on internalization and cytotoxicity of CD19-ricin A immunotoxins. Cancer Res 1994; 54(13): 3527-32.
45. Wiedlocha A, Sandvig K, Walzel H, Radzikowsky C, Olsnes S. Internalization and action of an immunotoxin containing mistletoe lectin A-chain. Cancer Res 1991; 51(3): 916-20.
46. Hayden MS, Linsley PS, Gayle MA, Bajorath J, Brady WA, Norris NA, et al. Single-chain mono- and bispecific antibody derivatives with novel biological properties and antitumour activity from a COS cell transient expression system. Therapeut Immunol 1994; 1(1): 3-15.
47. Newton DL, Xue Y, Olson KA, Fett JW, Rybak SM. Angiogenin single-chain immunofusions: Influence of peptide linkers and spacers between fusion protein domains. Biochemistry 1996; 35(2): 545-53.
48. Le Gall F, Kipriyanov SM, Moldenhauer G, Little M. Di-, tri- and tetrameric single chain Fv antibody fragments against human CD19: Effect of valency on cell binding. FEBS Lett 1999; 453(1-2): 164-8.
49. Kortt AA, Dolezal O, Power BE, Hudson PJ. Dimeric and trimeric antibodies: High avidity scFvs for cancer targeting. Biomol Eng 2001; 18(3): 95-108.
50. Calafat J, Molthoff C, Janssen H, Hilkens J. Endocytosis and intracellular routing of an antibody-ricin A chain conjugate. Cancer Res 1988; 48(13): 3822-7.
51. Casalini P, Caldera M, Canevari S, Menard S, Mezzanzanica D, Tosi E, et al. A critical comparison of three internalization assays applied to the evaluation of a given mAb as a toxin-carrier candidate. Cancer Immunol Immunother 1993; 37(1): 54-60.
52. Maiolo JR, Ferrer M, Ottinger EA. Effects of cargo molecules on the cellular uptake of arginine-rich cell-penetrating peptides. Biochim Biophys Acta 2005; 1712(2): 161-72.
53. Porro G, Lento P, Marcucci F, Gromo G, Modena D. Different cytotoxic activity and intracellular fate of an anti-CD5-momordin immunotoxin in normal compared to tumour cells. Cancer Immunol Immunother 1995; 40(4): 213-8.
54. Ravel S, Colombatti M, Casellas P. Internalization and intracellular fate of anti-CD5 monoclonal antibody and anti-CD5 ricin A-chain immunotoxin in human leukemic T cells. Blood 1992; 79(6): 1511-7.
55. Mere J, Morlon-Guyot J, Bonhoure A, Chiche L, Beaumelle B. Acid-triggered membrane insertion of Pseudomonas exotoxin A involves an original mechanism based on pH-regulated tryptophan exposure. J Biolog Chem 2005; 280(22): 21194-201.
56. Chaudhary VK, Jinno Y, FitzGerald D, Pastan I. Pseudomonas exotoxin contains a specific sequence at the carboxyl terminus that is required for cytotoxicity. Proc Natl Acad Sci USA 1990; 87(1): 308-12.
57. Seetharam S, Chaudhary VK, FitzGerald D, Pastan I. Increased cytotoxic activity of Pseudomonas exotoxin and two chimeric toxins ending in KDEL. J Biolog Chem 1991; 266(26): 17376-81.
58. Wang H, Dai J, Li B, Fan K, Peng L, Zhang D, et al. Expression, purification, and characterization of an immunotoxin containing a humanized anti-CD25 single-chain fragment variable antibody fused to a modified truncated Pseudomonas exotoxin A. Protein Expr Purif 2008; 58(1): 140-7.
59. Nachman M, Azad AR, Bailon P. Membrane-based receptor affinity chromatography. J Chromatogr 1992; 597(1-2): 155-66.
60. Wu M. Enhancement of immunotoxin activity using chemical and biological reagents. Br J Cancer 1997; 75(9): 1347-55.
61. Deonarain MP, Epenetos AA. Design, characterization and anti-tumour cytotoxicity of a panel of recombinant, mammalian ribonuclease-based immunotoxins. Br J Cancer 1998; 77(4): 537-46.
62. May RD, Finkelman FD, Wheeler HT, Uhr JW, Vitetta ES. Evaluation of ricin A chain-containing immunotoxins directed against different epitopes on the delta-chain of cell surface-associated IgD on murine B cells. J Immunol 1990; 144(9): 3637-42.
63. Press OW, Martin PJ, Thorpe PE, Vitetta ES. Ricin A-chain containing immunotoxins directed against different epitopes on the CD2 molecule differ in their ability to kill normal and malignant T cells. J Immunol 1988; 141(12): 4410-7.
64. Press OW, Vitetta ES, Farr AG, Hansen JA, Martin PJ. Evaluation of ricin A-chain immunotoxins directed against human T cells. Cell Immunol 1986; 102(1): 10-20.
65. Youle RJ, Neville DM, Jr. Kinetics of protein synthesis inactivation by ricin-anti-Thy 1.1 monoclonal antibody hybrids. Role of the ricin B subunit demonstrated by reconstitution. J Biolog Chem 1982; 257(4): 1598-601.
66. Vitetta ES, Uhr JW. Immunotoxins. Ann Rev Immunol 1985; 3: 197-212.
67. Adams GP, McCartney JE, Tai MS, Oppermann H, Huston JS, Stafford WF, 3rd, et al. Highly specific in vivo tumor targeting by monovalent and divalent forms of 741F8 anti-c-erbB-2 single-chain Fv. Cancer Res 1993; 53(17): 4026-34.
68. Adams GP, Schier R, McCall AM, Crawford RS, Wolf EJ, Weiner LM, et al. Prolonged in vivo tumour retention of a human diabody targeting the extracellular domain of human HER2/neu. Br J Cancer 1998; 77(9): 1405-12.
69. Wu AM, Chen W, Raubitschek A, Williams LE, Neumaier M, Fischer R, et al. Tumor localization of anti-CEA single-chain Fvs: Improved targeting by non-covalent dimers. Immunotechnology 1996; 2(1): 21-36
70. Beresford GW, Pavlinkova G, Booth BJ, Batra SK, Colcher D. Binding characteristics and tumor targeting of a covalently linked divalent CC49 single-chain antibody. Int J Cancer 1999; 81(6): 911-7.
71. Pavlinkova G, Beresford GW, Booth BJ, Batra SK, Colcher D. Pharmacokinetics and biodistribution of engineered single-chain antibody constructs of MAb CC49 in colon carcinoma xenografts. J Nucl Med 1999; 40(9): 1536-46.
72. Nielsen UB, Adams GP, Weiner LM, Marks JD. Targeting of bivalent anti-ErbB2 diabody antibody fragments to tumor cells is independent of the intrinsic antibody affinity. Cancer Res 2000; 60(22): 6434-40.
73. Holliger P, Prospero T, Winter G. "Diabodies": Small bivalent and bispecific antibody fragments. Proc Natl Acad Sci USA 1993; 90(14): 6444-8.
74. Arndt MA, Krauss J, Vu BK, Newton DL, Rybak SM. A dimeric angiogenin immunofusion protein mediates selective toxicity toward CD22+ tumor cells. J Immunother (1997) 2005; 28(3): 245-51.
75. Le Gall F, Reusch U, Little M, Kipriyanov SM. Effect of linker sequences between the antibody variable domains on the formation, stability and biological activity of a bispecific tandem diabody. Protein Eng Des Sel 2004; 17(4): 357-66.
76. Liu M, Wang X, Yin C, Zhang Z, Lin Q, Zhen Y, et al. A novel bivalent single chain Fv fragment inhibits tumor necrosis factor alpha action. Biotechnol Applied Biochem 2007; 50(pt 4): 173-9.
77. Thompson J, Stavrou S, Weetall M, Hexham JM, Digan ME, Wang Z, et al. Improved binding of a bivalent single-chain immunotoxin results in increased efficacy for in vivo T-cell depletion. Protein Eng 2001; 14(12): 1035-41.
78. Hu S, Shively L, Raubitschek A, Sherman M, Williams LE, Wong JY, et al. Minibody: A novel engineered anti-carcinoembryonic antigen antibody fragment (single-chain Fv-CH3) which exhibits rapid, high-level targeting of xenografts. Cancer Res 1996; 56(13): 3055-61.
79. Olafsen T, Tan GJ, Cheung CW, Yazaki PJ, Park JM, Shively JE, et al. Characterization of engineered anti-p185HER-2 (scFv-CH3)2 antibody fragments (minibodies) for tumor targeting. Protein Eng Des Sel 2004; 17(4): 315-23.
80. Yazaki PJ, Wu AM. Construction and characterization of minibodies for imaging and therapy of colorectal carcinomas. Methods Mol Biol (Clifton, NJ 2003; 207: 351-64.
81. Brown VI, Greene MI. Molecular and cellular mechanisms of receptor-mediated endocytosis. DNA Cell Biol 1991; 10(6): 399-409.
82. Guillemard V, Nedev HN, Berezov A, Murali R, Saragovi HU. HER2-mediated internalization of a targeted prodrug cytotoxic conjugate is dependent on the valency of the targeting ligand. DNA Cell Biol 2005; 24(6): 350-8.
83. Schmidt MM, Thurber GM, Wittrup KD. Kinetics of anticarcinoembryonic antigen antibody internalization: Effects of affinity, bivalency, and stability. Cancer Immunol Immunother 2008.
84. Duke-Cohan JS, Morimoto C, Schlossman SF. Targeting of an activated T-cell subset using a bispecific antibody-toxin conjugate directed against CD4 and CD26. Blood 1993; 82(7): 2224-34.
85. Duke-Cohan JS, Morimoto C, Schlossman SF. Depletion of the helper/ inducer (memory) T cell subset using a bispecific antibodytoxin conjugate directed against CD4 and CD29. Transplantation 1993; 56(5): 1188-96.
86. Daniels TR, Ng PP, Delgado T, Lynch MR, Schiller G, Helguera G, et al. Conjugation of an anti transferrin receptor IgG3-avidin fusion protein with biotinylated saporin results in significant enhancement of its cytotoxicity against malignant hematopoietic cells. Mol Cancer Ther 2007; 6(11): 2995-3008.
87. Bolognesi A, Tazzari PL, Legname G, Olivieri F, Modena D, Conte R, et al. Anti-CD30 immunotoxins with native and recombinant dianthin 30. Cancer Immunol Immunother 1995; 40(2): 109-14.
88. Huhn M, Sasse S, Tur MK, Matthey B, Schinkothe T, Rybak SM, et al. Human angiogenin fused to human CD30 ligand (AngCD30L) exhibits specific cytotoxicity against CD30-positive lymphoma. Cancer Res 2001; 61(24): 8737-42.
89. Dalken B, Giesubel U, Knauer SK, Wels WS. Targeted induction of apoptosis by chimeric granzyme B fusion proteins carrying antibody and growth factor domains for cell recognition. Cell Death Differ 2006; 13(4): 576-85.
90. Stahnke B, Thepen T, Stöcker M, Rosinke R, Jost E, Fischer R, et al. Granzyme B-H22(scFv), a human immunotoxin targeting CD64 in acute myeloid leukemia of monocytic subtypes. Mol Cancer Ther 2008; 7(9): 2924-32.
91. Benigni F, Canevari S, Gadina M, Adobati E, Ferreri AJ, Di Celle EF, et al. Preclinical evaluation of the ribosome-inactivating proteins PAP-1, PAP-S and RTA in mice. Int J Immunopharmacol 1995; 17(10): 829-39.
92. Onda M, Nagata S, FitzGerald DJ, Beers R, Fisher RJ, Vincent JJ, et al. Characterization of the B cell epitopes associated with a truncated form of Pseudomonas exotoxin (PE38) used to make immunotoxins for the treatment of cancer patients. J Immunol 2006; 177(12): 8822-34.
93. Tommasi M, Castelletti D, Pasti M, Fracasso G, Lorenzetti I, Sartoris S, et al. Identification of ricin A-chain HLA class II-restricted epitopes by human T-cell clones. Clin Exp Immunol 2001; 125(3): 391-400.
94. Vago R, Marsden CJ, Lord JM, Ippoliti R, Flavell DJ, Flavell SU, et al. Saporin and ricin A chain follow different intracellular routes to enter the cytosol of intoxicated cells. FEBS J 2005; 272(19): 4983-95.
95. Wu YN, Gadina M, Tao-Cheng JH, Youle RJ. Retinoic acid disrupts the Golgi apparatus and increases the cytosolic routing of specific protein toxins. J Cell Biol 1994; 125(4): 743-53.
96. Davol PA, Bizuneh A, Frackelton AR, Jr. Wortmannin, a phosphoinositide 3-kinase inhibitor, selectively enhances cytotoxicity of receptor- directed-toxin chimeras in vitro and in vivo. Anticancer Res 1999; 19(3A): 1705-13.
97. Elson-Schwab L, Garner OB, Schuksz M, Crawford BE, Esko JD, Tor Y. Guanidinylated neomycin delivers large, bioactive cargo into cells through a heparan sulfate-dependent pathway. J Biol Chem 2007; 282(18): 13585-91.
98. Lai PS, Pai CL, Peng CL, Shieh MJ, Berg K, Lou PJ. Enhanced cytotoxicity of saporin by polyamidoamine dendrimer conjugation and photochemical internalization. J Biomed Mater Res A 2007.
99. Selbo PK, Hogset A, Prasmickaite L, Berg K. Photochemical internalisation: A novel drug delivery system. Tumour Biol 2002; 23(2): 103-12.
100. Weyergang A, Selbo PK, Berg K. Photochemically stimulated drug delivery increases the cytotoxicity and specificity of EGF-saporin. J Control Release 2006; 111(1-2): 165-73.
101. Yip WL, Weyergang A, Berg K, Tonnesen HH, Selbo PK. Targeted delivery and enhanced cytotoxicity of cetuximab-saporin by photochemical internalization in EGFR-positive cancer cells. Mol Pharm 2007; 4(2): 241-51.
102. Selbo PK, Sivam G, Fodstad O, Sandvig K, Berg K. Photochemical internalisation increases the cytotoxic effect of the immunotoxin MOC31-gelonin. Int J Cancer 2000; 87(6): 853-9.
103. Sparg SG, Light ME, van Staden J. Biological activities and distribution of plant saponins. J Ethnopharmacol 2004; 94(2-3): 219-43.
104. Hebestreit P, Melzig MF. Cytotoxic activity of the seeds from Agrostemma githago var. githago. Planta Med 2003; 69(10): 921-5.
105. Heisler I, Sutherland M, Bachran C, Hebestreit P, Schnitger A, Melzig MF, et al. Combined application of saponin and chimeric toxins drastically enhances the targeted cytotoxicity on tumor cells. J Control Release 2005; 106(1-2): 123-37.
106. Bachran C, Sutherland M, Heisler I, Hebestreit P, Melzig MF, Fuchs H. The saponin-mediated enhanced uptake of targeted saporin-based drugs is strongly dependent on the saponin structure. Exp Biol Med (Maywood) 2006; 231(4): 412-20.
107. Bachran C, Heisler I, Bachran D, Dassler K, Ervens J, Melzig MF, et al. Chimeric toxins inhibit growth of primary oral squamous cell carcinoma cells. Cancer Biol Ther 2008; 7(2): 237-42.
108. Stewart KM, Horton KL, Kelley SO. Cell-penetrating peptides as delivery vehicles for biology and medicine. Org Biomol Chem 2008; 6(13): 2242-55.
109. Green M, Loewenstein PM. Autonomous functional domains of chemically synthesized human immunodeficiency virus tat transactivator protein. Cell 1988; 55(6): 1179-88.
110. Fuchs H, Bachran C, Heisler I, Sutherland M. A closer look at protein transduction domains as a tool in drug delivery. Curr Nanosci 2005; 1(2): 117-24.
111. Oess S, Hildt E. Novel cell permeable motif derived from the PreS2-domain of hepatitis-B virus surface antigens. Gene Ther 2000; 7(9): 750-8.
112. Morris MC, Depollier J, Mery J, Heitz F, Divita G. A peptide carrier for the delivery of biologically active proteins into mammalian cells. Nat Biotechnol 2001; 19(12): 1173-6.
113. Cartier R, Reszka R. Utilization of synthetic peptides containing nuclear localization signals for nonviral gene transfer systems. Gene Ther 2002; 9(3): 157-67.
114. Schwarze SR, Ho A, Vocero-Akbani A, Dowdy SF. In vivo protein transduction: Delivery of a biologically active protein into the mouse. Science 1999; 285(5433): 1569-72.
115. Astriab-Fisher A, Sergueev D, Fisher M, Shaw BR, Juliano RL. Conjugates of antisense oligonucleotides with the Tat and antennapedia cell-penetrating peptides: Effects on cellular uptake, binding to target sequences, and biologic actions. Pharm Res 2002; 19(6): 744-54.
116. Nori A, Jensen KD, Tijerina M, Kopeckova P, Kopecek J. Tatconjugated synthetic macromolecules facilitate cytoplasmic drug delivery to human ovarian carcinoma cells. Bioconjug Chem 2003; 14(1): 44-50.
117. Torchilin VP, Rammohan R, Weissig V, Levchenko TS. TAT peptide on the surface of liposomes affords their efficient intracellular delivery even at low temperature and in the presence of metabolic inhibitors. Proc Natl Acad Sci USA 2001; 98(15): 8786-91.
118. Lewin M, Carlesso N, Tung CH, Tang XW, Cory D, Scadden DT, et al. Tat peptide-derivatized magnetic nanoparticles allow in vivo tracking and recovery of progenitor cells. Nat Biotechnol 2000; 18(4): 410-4.
119. Alves ID, Goasdoue N, Correia I, Aubry S, Galanth C, Sagan S, et al. Membrane interaction and perturbation mechanisms induced by two cationic cell penetrating peptides with distinct charge distribution. Biochim Biophys Acta 2008; 1780(7-8): 948-59.
120. Hallbrink M, Floren A, Elmquist A, Pooga M, Bartfai T, Langel U. Cargo delivery kinetics of cell-penetrating peptides. Biochim Biophys Acta 2001; 1515(2): 101-9.
121. Jones AT. Gateways and tools for drug delivery: Endocytic pathways and the cellular dynamics of cell penetrating peptides. Int J Pharm 2008; 354(1-2): 34-8.
122. Saalik P, Elmquist A, Hansen M, Padari K, Saar K, Viht K, et al. Protein cargo delivery properties of cell-penetrating peptides. A comparative study. Bioconjug Chem 2004; 15(6): 1246-53.
123. Yandek LE, Pokorny A, Floren A, Knoelke K, Langel U, Almeida PF. Mechanism of the cell-penetrating peptide transportan 10 permeation of lipid bilayers. Biophys J 2007; 92(7): 2434-44.
124. Fittipaldi A, Ferrari A, Zoppe M, Arcangeli C, Pellegrini V, Beltram F, et al. Cell membrane lipid rafts mediate caveolar endocytosis of HIV-1 Tat fusion proteins. J Biol Chem 2003; 278(36): 34141-9.
125. Richard JP, Melikov K, Brooks H, Prevot P, Lebleu B, Chernomordik LV. Cellular uptake of unconjugated TAT peptide involves clathrin-dependent endocytosis and heparan sulfate receptors. J Biol Chem 2005; 280(15): 15300-6.
126. Horton KL, Stewart KM, Fonseca SB, Guo Q, Kelley SO. Mitochondria- penetrating peptides. Chem Biol 2008; 15(4): 375-82.
127. Zhao K, Zhao GM, Wu D, Soong Y, Birk AV, Schiller PW, et al. Cell-permeable peptide antioxidants targeted to inner mitochondrial membrane inhibit mitochondrial swelling, oxidative cell death, and reperfusion injury. J Biol Chem 2004; 279(33): 34682-90.
128. Del Gaizo V, Payne RM. A novel TAT-mitochondrial signal sequence fusion protein is processed, stays in mitochondria, and crosses the placenta. Mol Ther 2003; 7(6): 720-30.
129. Vousden KH, Lu X. Live or let die: The cell's response to p53. Nat Rev Cancer 2002; 2(8): 594-604.
130. Harbour JW, Worley L, Ma D, Cohen M. Transducible peptide therapy for uveal melanoma and retinoblastoma. Arch Ophthalmol 2002; 120(10): 1341-6.
131. Fulda S, Wick W, Weller M, Debatin KM. Smac agonists sensitize for Apo2L/ TRAIL- or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo. Nat Med 2002; 8(8): 808-15.
132. Datta K, Sundberg C, Karumanchi SA, Mukhopadhyay D. The 104-123 amino acid sequence of the beta-domain of von HippelLindau gene product is sufficient to inhibit renal tumor growth and invasion. Cancer Res 2001; 61(5): 1768-75.
133. Semenza GL. HIF-1, O(2), and the 3 PHDs: How animal cells signal hypoxia to the nucleus. Cell 2001; 107(1): 1-3.
134. Inoue M, Mukai M, Hamanaka Y, Tatsuta M, Hiraoka M, KizakaKondoh S. Targeting hypoxic cancer cells with a protein prodrug is effective in experimental malignant ascites. Int J Oncol 2004; 25(3): 713-20.
135. Harada H, Kizaka-Kondoh S, Hiraoka M. Antitumor protein therapy; application of the protein transduction domain to the development of a protein drug for cancer treatment. Breast Cancer 2006; 13(1): 16-26.
136. Wadia JS, Dowdy SF. Transmembrane delivery of protein and peptide drugs by TAT-mediated transduction in the treatment of cancer. Adv Drug Deliv Rev 2005; 57(4): 579-96.
137. Keller J, Heisler I, Tauber R, Fuchs H. Development of a novel molecular adapter for the optimization of immunotoxins. J Control Release 2001; 74(1-3): 259-61.
138. Snyder EL, Saenz CC, Denicourt C, Meade BR, Cui XS, Kaplan IM, et al. Enhanced targeting and killing of tumor cells expressing the CXC chemokine receptor 4 by transducible anticancer peptides. Cancer Res 2005; 65(23): 10646-50.
139. Jiang T, Olson ES, Nguyen QT, Roy M, Jennings PA, Tsien RY. Tumor imaging by means of proteolytic activation of cellpenetrating peptides. Proc Natl Acad Sci USA 2004; 101(51): 17867-72.
140. Goldmacher VS, Scott CF, Lambert JM, McIntyre GD, Blattler WA, Collnhson AR, et al. Cytotoxicity of gelonin and its conjugates with antibodies is determined by the extent of their endocytosis. J Cell Physiol 1989; 141(1): 222-34.
141. Olsnes S, Sandvig K, Petersen OW, van Deurs B. Immunotoxins - entry into cells and mechanisms of action. Immunol today 1989; 10(9): 291-5.
142. Sandvig K, van Deurs B. Endocytosis, intracellular transport, and cytotoxic action of Shiga toxin and ricin. Physiol Rev 1996; 76(4): 949-66.
143. Timar J, McIntosh DP, Henry R, Cumber AJ, Parnell GD, Davies AJ. The effect of ricin B chain on the intracellular trafficking of an A chain immunotoxin. Br J Cancer 1991; 64(4): 655-62.
144. May RD, Wheeler HT, Finkelman FD, Uhr JW, Vitetta ES. Intracellular routing rather than cross-linking or rate of internalization determines the potency of immunotoxins directed against different epitopes of sIgD on murine B cells. Cell Immunol 1991; 135(2): 490-500.
145. Marsh JW. Antibody-mediated routing of diphtheria toxin in murine cells results in a highly efficacious immunotoxin. J Biolog Chem 1988; 263(31): 15993-9.
146. Hudson TH, Neville DM, Jr. Enhancement of immunotoxin action: manipulation of the cellular routing of proteins. Cancer Treat Res 1988; 37: 371-89.
147. Sandvig K, van Deurs B. Delivery into cells: Lessons learned from plant and bacterial toxins. Gene Ther 2005; 12(11): 865-72.
148. Carroll SF, Collier RJ. Active site of Pseudomonas aeruginosa exotoxin A. Glutamic acid 553 is photolabeled by NAD and shows functional homology with glutamic acid 148 of diphtheria toxin. J Biolog Chem 1987; 262(18): 8707-11.
149. Neville DM, Jr., Hudson TH. Transmembrane transport of diphtheria toxin, related toxins, and colicins. Ann Rev Biochem 1986; 55: 195-224.
150. Kaul P, Silverman J, Shen WH, Blanke SR, Huynh PD, Finkelstein A, et al. Roles of Glu 349 and Asp 352 in membrane insertion and translocation by diphtheria toxin. Protein Sci 1996; 5(4): 687-92.
151. Gu M, Gordon VM, Fitzgerald DJ, Leppla SH. Furin regulates both the activation of Pseudomonas exotoxin A and the Quantity of the toxin receptor expressed on target cells. Infect Immun 1996; 64(2): 524-7
152. Inocencio NM, Moehring JM, Moehring TJ. Furin activates Pseudomonas exotoxin A by specific cleavage in vivo and in vitro. J Biolog Chem 1994; 269(50): 31831-5.
153. Ornatowski W, Poschet JF, Perkett E, Taylor-Cousar JL, Deretic V. Elevated furin levels in human cystic fibrosis cells result in hypersusceptibility to exotoxin A-induced cytotoxicity. J Clin Invest 2007; 117(11): 3489-97.
154. Sarac MS, Cameron A, Lindberg I. The furin inhibitor hexa-D-arginine blocks the activation of Pseudomonas aeruginosa exotoxin A in vivo. Infect Immun 2002; 70(12): 7136-9.
155. Du X, Ho M, Pastan I. New immunotoxins targeting CD123, a stem cell antigen on acute myeloid leukemia cells. J Immunother 2007; 30(6): 607-13.
156. Kreitman RJ, Pastan I. Importance of the glutamate residue of KDEL in increasing the cytotoxicity of Pseudomonas exotoxin derivatives and for increased binding to the KDEL receptor. The Biochemical journal 1995; 307 (Pt 1): 29-37.
157. Mansfield E, Pastan I, FitzGerald DJ. Characterization of RFB4-Pseudomonas exotoxin A immunotoxins targeted to CD22 on B-cell malignancies. Bioconjug Chem 1996; 7(5): 557-63.
158. O'Hare M, Brown AN, Hussain K, Gebhardt A, Watson G, Roberts LM, et al. Cytotoxicity of a recombinant ricin-A-chain fusion protein containing a proteolytically-cleavable spacer sequence. FEBS letters 1990; 273(1-2): 200-4.
159. Zhao J, Zhang LH, Jia LT, Zhang L, Xu YM, Wang Z, et al. Secreted antibody/granzyme B fusion protein stimulates selective killing of HER2-overexpressing tumor cells. J Biolog Chem 2004; 279(20): 21343-8
160. Goyal A, Batra JK. Inclusion of a furin-sensitive spacer enhances the cytotoxicity of ribotoxin restrictocin containing recombinant single-chain immunotoxins. The Biochemical journal 2000; 345 Pt 2: 247-54.
161. Wang T, Zhao J, Ren JL, Zhang L, Wen WH, Zhang R, et al. Recombinant immunoproapoptotic proteins with furin site can translocate and kill HER2-positive cancer cells. Cancer Res 2007; 67(24): 11830-9
162. Wales R, Chaddock JA, Roberts LM, Lord JM. Addition of an ER retention signal to the ricin A chain increases the cytotoxicity of the holotoxin. Experimental cell Res 1992; 203(1): 1-4.
163. Schmid B, Chung DE, Warnecke A, Fichtner I, Kratz F. Albuminbinding prodrugs of camptothecin and doxorubicin with an Ala-Leu-Ala-Leu-linker that are cleaved by cathepsin B: Synthesis and antitumor efficacy. Bioconjug Chem 2007; 18(3): 702-16.
164. Harada M, Sakakibara H, Yano T, Suzuki T, Okuno S. Determinants for the drug release from T-0128, camptothecin analoguecarboxymethyl dextran conjugate. J Control Release 2000; 69(3): 399-412.
165. Vasey PA, Kaye SB, Morrison R, Twelves C, Wilson P, Duncan R, et al. Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl) methacrylamide copolymer doxorubicin]: First member of a new class of chemotherapeutic agents-drug-polymer conjugates. Cancer Research Campaign Phase I/II Committee. Clin Cancer Res 1999; 5(1): 83-94.
166. Ebert W, Knoch H, Werle B, Trefz G, Muley T, Spiess E. Prognostic value of increased lung tumor tissue cathepsin B. Anticancer Res 1994; 14(3A): 895-9.
167. Goel A, Chauhan SS. Role of proteases in tumor invasion and metastasis. Indian J experimental biology 1997; 35(6): 553-64.
168. Kos J, Stabuc B, Schweiger A, Krasovec M, Cimerman N, Kopitar-Jerala N, et al. Cathepsins B, H, and L and their inhibitors stefin A and cystatin C in sera of melanoma patients. Clin Cancer Res 1997; 3(10): 1815-22.
169. Kim SH, Jeong JH, Lee SH, Kim SW, Park TG. PEG conjugated VEGF siRNA for anti-angiogenic gene therapy. J Control Release 2006; 116(2): 123-9
170. Zhou J, Bai Y, Weiner H. Proteolysis prevents in vivo chimeric fusion protein import into yeast mitochondria. Cytosolic cleavage and subcellular distribution. J Biol Chem 1995; 270(28): 16689-93.
171. Cerretti DP, Kozlosky CJ, Mosley B, Nelson N, Van Ness K, Greenstreet TA, et al. Molecular cloning of the interleukin-1 beta converting enzyme. Science 1992; 256(5053): 97-100.
172. Mariathasan S, Newton K, Monack DM, Vucic D, French DM, Lee WP, et al. Differential activation of the inflammasome by caspase-1 adaptors ASC and Ipaf. Nature 2004; 430(6996): 213-8.
173. Thornberry NA, Bull HG, Calaycay JR, Chapman KT, Howard AD, Kostura MJ, et al. A novel heterodimeric cysteine protease is required for interleukin-1 beta processing in monocytes. Nature 1992; 356(6372): 768-74.
174. Yamanaka K, Clark R, Dowgiert R, Hurwitz D, Shibata M, Rich BE, et al. Expression of interleukin-18 and caspase-1 in cutaneous T-cell lymphoma. Clin Cancer Res 2006; 12(2): 376-82.
175. Prochiantz A. Getting hydrophilic compounds into cells: Lessons from homeopeptides. Curr Opin Neurobiol 1996; 6(5): 629-34.
176. Rojas M, Donahue JP, Tan Z, Lin YZ. Genetic engineering of proteins with cell membrane permeability. Nat Biotechnol 1998; 16(4): 370-5.
177. Hetzel C, Bachran C, Fischer R, Fuchs H, Barth S, Stöcker M. Small cleavable adapters enhance the specific cytotoxicity of a humanized immunotoxin directed against CD64-positive cells. J Immunother 2008; 31(4): 370-6.
178. Bachran C, Heisler I, Fuchs H, Sutherland M. Influence of protein transduction domains on target-specific chimeric proteins. Biochem Biophys Res Commun 2005; 337(2): 602-9.
179. Debbage P. Targeted drugs and nanomedicine: Present and future. Curr Pharm Des 2009; 15(2): 153-72.
180. Frieden M, Orum H. Locked nucleic acid holds promise in the treatment of cancer. Curr Pharm Des 2008; 14(11): 1138-42.
181. Katsman A, Umezawa K, Bonavida B. Chemosensitization and immunosensitization of resistant cancer cells to apoptosis and inhibition of metastasis by the specific NF-kappaB inhibitor DHMEQ. Curr Pharm Des 2009; 15(7): 792-808.